Functional analysis of microRNAs in human hepatocellular cancer stem cells

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 1, 2012, Pages 160-173

  Meng, Fanyin ^a   Glaser, Shannon S ^a   Francis, Heather ^a   Demorrow, Sharon ^a   Han, Yuyan ^a   Passarini, Jenna D ^b   Stokes, Allison ^a   Cleary, John P ^b   Liu, Xiuping ^c   Venter, Julie ^a   Kumar, Preetham ^b   Priester, Sally ^a   Hubble, Levi ^a   Staloch, Dustin ^a   Sharma, Jay ^b   Liu, Chang Gong ^c   Alpini, Gianfranco ^a,d  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b Celprogen Inc   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Human hepatocellular cancer stem cells (HSCs); Interleukin 6 (IL 6); Invasion; MicroRNAs (miRNAs); Twist

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; MICRORNA; NUCLEAR PROTEIN; PYRIDINE DERIVATIVE; SORAFENIB; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

ANIMAL; ARTICLE; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL MOTION; CELL SURVIVAL; CLUSTER ANALYSIS; CYTOLOGY; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PLURIPOTENT STEM CELL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, SCID; MICRORNAS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NUCLEAR PROTEINS; PLURIPOTENT STEM CELLS; PYRIDINES; TWIST TRANSCRIPTION FACTOR;

EID: 84855176010     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01282.x     Document Type: Article

References (47)

1. Adams JM, Strasser A. Is tumor growth sustained by rare cancer stem cells or dominant clones? Cancer Res. 2008; 68: 4018-21.
2. Alvero AB, Chen R, Fu HH, et al Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle. 2009; 8: 158-66.
3. Mishra L, Banker T, Murray J, et al Liver stem cells and hepatocellular carcinoma. Hepatology. 2009; 49: 318-29.
4. Rosa A, Brivanlou AH. microRNAs in early vertebrate development. Cell Cycle. 2009; 8, 3513-20.
5. Sartipy P, Olsson B, Hyllner J, Synnergren J. Regulation of 'stemness' and stem cell differentiation by microRNAs. IDrugs. 2009; 12: 492-6.
6. Kashyap V, Rezende NC, Scotland KB, et al Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev. 2009; 18: 1093-108.
7. Hornstein E, Shomron N. Canalization of development by microRNAs. Nat Genet. 2006; 38: S20-4.
8. Chang TC, Yu D, Lee YS, et al Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008; 40: 43-50.
9. Zhao C, Sun G, Li S, et al MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. Proc Natl Acad Sci USA. 2010; 107: 1876-81.
10. Melton C, Judson RL, Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature. 2010; 463: 621-6.
11. Wellner U, Schubert J, Burk UC, et al The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11: 1487-95.
12. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009; 139: 693-706.
13. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene. 2003; 22: 5093-107.
14. Sell S, Leffert HL. Liver cancer stem cells. J Clin Oncol. 2008; 26: 2800-5.
15. Meng F, Wehbe-Janek H, Henson R, et al Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene. 2008; 27: 378-86.
16. Meng F, Henson R, Wehbe-Janek H, et al The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem. 2007; 282: 8256-64.
17. Cheng GZ, Zhang W, Wang LH. Regulation of cancer cell survival, migration, and invasion by Twist: AKT2 comes to interplay. Cancer Res. 2008; 68: 957-60.
18. Katoh Y, Katoh M. Hedgehog signaling, epithelial-to-mesenchymal transition and miRNA (review). Int J Mol Med. 2008; 22: 271-5.
19. Ma S, Lee TK, Zheng BJ, et al CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene. 2008; 27: 1749-58.
20. Ji J, Yamashita T, Budhu A, et al Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells. Hepatology. 2009; 50: 472-80.
21. Sancho-Bru P, Najimi M, Caruso M, et al Stem and progenitor cells for liver repopulation: can we standardise the process from bench to bedside? Gut. 2009; 58: 594-603.
22. Palmer DH. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 2498; author reply 9.
23. Liu L, Cao Y, Chen C, et al Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006; 66: 11851-8.
24. Matsuo N, Shiraha H, Fujikawa T, et al Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer. 2009; 9: 240.
25. Lee TK, Poon RT, Yuen AP, et al Twist overexpression correlates with hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2006; 12: 5369-76.
26. Lee YB, Bantounas I, Lee DY, et al Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res. 2009; 37: 123-8.
27. Wang B, Hsu SH, Majumder S, et al TGFbeta-mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene. 2010; 29: 1787-97.
28. Pietrangelo A, Oude Elferink R, Prieto J, Bacon BR. Genetics in liver diseases. J Hepatol. 2007; 46: 1143-8.
29. Calin GA, Liu CG, Ferracin M, et al Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 2007; 12: 215-29.
30. Tang Y, Kitisin K, Jogunoori W, et al Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci USA. 2008; 105: 2445-50.
31. Logan RM, Stringer AM, Bowen JM, et al The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev. 2007; 33: 448-60.
32. Sempere LF, Freemantle S, Pitha-Rowe I, et al Expression profiling of mammalian microRNAs uncovers a subset of brain-expressed microRNAs with possible roles in murine and human neuronal differentiation. Genome Biol. 2004; 5: R13.
33. Houbaviy HB, Murray MF, Sharp PA. Embryonic stem cell-specific MicroRNAs. Dev Cell. 2003; 5: 351-8.
34. Rybak A, Fuchs H, Smirnova L, et al A feedback loop comprising lin-28 and let-7 controls pre-let-7 maturation during neural stem-cell commitment. Nat Cell Biol. 2008; 10: 987-93.
35. Newman MA, Thomson JM, Hammond SM. Lin-28 interaction with the Let-7 precursor loop mediates regulated microRNA processing. RNA. 2008; 14: 1539-49.
36. Viswanathan SR, Daley GQ, Gregory RI. Selective blockade of microRNA processing by Lin28. Science. 2008; 320: 97-100.
37. Heo I, Joo C, Cho J, et al Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell. 2008; 32: 276-84.
38. Tokumaru S, Suzuki M, Yamada H, et al let-7 regulates Dicer expression and constitutes a negative feedback loop. Carcinogenesis. 2008; 29: 2073-7.
39. Selbach M, Schwanhausser B, Thierfelder N, et al Widespread changes in protein synthesis induced by microRNAs. Nature. 2008; 455: 58-63.
40. Lu J, Getz G, Miska EA, et al MicroRNA expression profiles classify human cancers. Nature. 2005; 435: 834-8.
41. Choong ML, Yang HH, McNiece I. MicroRNA expression profiling during human cord blood-derived CD34 cell erythropoiesis. Exp Hematol. 2007; 35: 551-64.
42. Yan LX, Huang XF, Shao Q, et al MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA. 2008; 14: 2348-60.
43. Nakajima G, Hayashi K, Xi Y, et al Non-coding MicroRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genom Proteom. 2006; 3: 317-24.
44. Lee EJ, Gusev Y, Jiang J, et al Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer. 2007; 120: 1046-54.
45. Shi L, Cheng Z, Zhang J, et al hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res. 2008; 1236: 185-93.
46. Calin GA, Pekarsky Y, Croce CM. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007; 20: 425-37.
47. Cheung O, Puri P, Eicken C, et al Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology. 2008; 48: 1810-20.